<p>Bright Minds Biosciences Inc.（納斯達克代碼：DRUG - 獲取免費報告）在覆蓋該股票的八家研究公司中被評為 “適度買入”，Marketbeat 報告稱。一位分析師對該股票給予了持有建議，七位分析師則給予了買入建議。在過去一年中，更新了對該股票覆蓋的經紀人中，平均一年目標價為 115.40 美元。</p>
<ul>
<li>生物科技行業的邊緣：兩隻潛力巨大的股票</li>
</ul>
<p>DRUG 已成為幾份研究分析報告的主題。HC Wainwright 在 12 月 30 日的研究報告中重新發布了 “買入” 評級，並對 Bright Minds Biosciences 的股票設定了 115.00 美元的目標價。Zacks Research 在 12 月 2 日的研究報告中將 Bright Minds Biosciences 的股票評級從 “強力買入” 下調至 “持有”。Wall Street Zen 在週六的報告中將 Bright Minds Biosciences 的股票評級從 “持有” 下調至 “賣出”。Cantor Fitzgerald 在 12 月 1 日的報告中重申了對 Bright Minds Biosciences 股票的 “增持” 評級。最後，Robert W. Baird 在週三的報告中設定了 Bright Minds Biosciences 的目標價為 142.00 美元。</p>
<p><strong>查看我們關於 Bright Minds Biosciences 的最新報告</strong></p>
<h2>Bright Minds Biosciences 的機構交易</h2>
<ul>
<li>Bright Minds Biosciences 股票暴漲近 1500%</li>
</ul>
<p>一些機構投資者最近調整了對 DRUG 的持股。Sio Capital Management LLC 在第二季度將其在 Bright Minds Biosciences 的持股增加了 0.9%。Sio Capital Management LLC 現在擁有 512,338 股該公司的股票，價值 13,377,000 美元，在上個季度又購買了 4,776 股。Vivo Capital LLC 在第三季度將其在 Bright Minds Biosciences 的持股增加了 99.4%。Vivo Capital LLC 現在擁有 501,617 股該公司的股票，價值 30,428,000 美元，在上個季度又收購了 250,045 股。Braidwell LP 在第三季度購買了價值 18,422,000 美元的 Bright Minds Biosciences 新頭寸。Millennium Management LLC 在第一季度將其在 Bright Minds Biosciences 的持股增加了 376.9%。Millennium Management LLC 現在擁有 192,557 股該公司的股票，價值 6,946,000 美元，在此期間又收購了 152,178 股。最後，Balyasny Asset Management L.P. 在第三季度收購了價值 11,339,000 美元的 Bright Minds Biosciences 新頭寸。對沖基金和其他機構投資者持有該公司 40.52% 的股票。</p>
<h2>Bright Minds Biosciences 股票下跌 3.6%</h2>
<p>納斯達克 DRUG 週一開盤價為 86.75 美元。該公司的 50 日移動平均價格為 73.17 美元，200 日移動平均價格為 53.97 美元。Bright Minds Biosciences 的 12 個月低點為 23.17 美元，12 個月高點為 123.75 美元。該公司的市值為 6.7578 億美元，市盈率為-71.11，貝塔值為-6.15。</p>
<h2>關於 Bright Minds Biosciences</h2>
<p>（獲取免費報告）</p>
<p>Bright Minds Biosciences Inc. 在納斯達克交易，代碼為 DRUG，是一家臨牀階段的生物技術公司，專注於開發用於心理健康和神經退行性疾病的新型小分子治療藥物。該公司的研究利用專有化學平台創造源自迷幻藥結構的調節血清素和神經保護化合物。Bright Minds 旨在通過口服治療解決重度抑鬱症、創傷後應激障礙和阿爾茨海默病等疾病的未滿足需求。</p>
<p>該公司的主要候選藥物 BMB-101 是一種口服的 5-HT2A 受體調節化合物，正在臨牀開發中用於情緒和焦慮障礙。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Bright Minds Biosciences</li>
<li>巨大的機器人推廣正在進行中</li>
<li>請勿刪除，立即閲讀</li>
<li>免費：可能改變您生活的加密峯會</li>
<li>新的黃金價格目標</li>
<li>家族信託如何幫助保護您的財富</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於 Bright Minds Biosciences 嗎？</h2>
<p>在您考慮 Bright Minds Biosciences 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Bright Minds Biosciences 並不在名單上。</p>
<p>雖然 Bright Minds Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DRUG

<p>Bright Minds Biosciences Inc.（納斯達克代碼：DRUG）獲得了八家研究公司的 “適度買入” 共識評級。一位分析師將其評級為持有，而七位分析師推薦買入。平均一年期目標價為 115.40 美元。最近的報告包括 HC Wainwright 的買入評級，目標價為 115 美元，Zacks 將評級下調至持有，以及 Cantor Fitzgerald 的增持評級。機構投資者持有該股票的 40.52%，該股票的交易活動非常活躍。該股票開盤價為 86.75 美元，12 個月的價格區間為 23.17 美元至 123.75 美元</p>

<p>Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) has been assigned an average rating of &#34;Moderate Buy&#34; from the eight research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $115.40.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc.（納斯達克代碼：DRUG - 獲取免費報告）在覆蓋該股票的八家研究公司中被評為 “適度買入”，Marketbeat 報告稱。一位分析師對該股票給予了持有建議，七位分析師則給予了買入建議。在過去一年中，更新了對該股票覆蓋的經紀人中，平均一年目標價為 115.40 美元。</p>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行業的邊緣：兩隻潛力巨大的股票</li>
</ul>
</div><p>DRUG has been the topic of several research analyst reports. HC Wainwright reissued a &#34;buy&#34; rating and issued a $115.00 target price on shares of Bright Minds Biosciences in a research report on Tuesday, December 30th. Zacks Research downgraded shares of Bright Minds Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, December 2nd. Wall Street Zen lowered shares of Bright Minds Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Cantor Fitzgerald restated an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a report on Monday, December 1st. Finally, Robert W. Baird set a $142.00 target price on Bright Minds Biosciences in a report on Wednesday.</p>
<div class="lb-trans"><p>DRUG 已成為幾份研究分析報告的主題。HC Wainwright 在 12 月 30 日的研究報告中重新發布了 “買入” 評級，並對 Bright Minds Biosciences 的股票設定了 115.00 美元的目標價。Zacks Research 在 12 月 2 日的研究報告中將 Bright Minds Biosciences 的股票評級從 “強力買入” 下調至 “持有”。Wall Street Zen 在週六的報告中將 Bright Minds Biosciences 的股票評級從 “持有” 下調至 “賣出”。Cantor Fitzgerald 在 12 月 1 日的報告中重申了對 Bright Minds Biosciences 股票的 “增持” 評級。最後，Robert W. Baird 在週三的報告中設定了 Bright Minds Biosciences 的目標價為 142.00 美元。</p>
</div><p><strong>View Our Latest Report on Bright Minds Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Bright Minds Biosciences 的最新報告</strong></p>
</div><h2>Institutional Trading of Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 的機構交易</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票暴漲近 1500%</li>
</ul>
</div><p>A number of institutional investors have recently modified their holdings of DRUG. Sio Capital Management LLC increased its position in Bright Minds Biosciences by 0.9% during the 2nd quarter. Sio Capital Management LLC now owns 512,338 shares of the company's stock worth $13,377,000 after purchasing an additional 4,776 shares in the last quarter. Vivo Capital LLC increased its position in shares of Bright Minds Biosciences by 99.4% in the third quarter. Vivo Capital LLC now owns 501,617 shares of the company's stock worth $30,428,000 after acquiring an additional 250,045 shares in the last quarter. Braidwell LP purchased a new position in shares of Bright Minds Biosciences in the 3rd quarter valued at $18,422,000. Millennium Management LLC raised its stake in shares of Bright Minds Biosciences by 376.9% in the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company's stock valued at $6,946,000 after acquiring an additional 152,178 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Bright Minds Biosciences during the 3rd quarter valued at $11,339,000. Hedge funds and other institutional investors own 40.52% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對 DRUG 的持股。Sio Capital Management LLC 在第二季度將其在 Bright Minds Biosciences 的持股增加了 0.9%。Sio Capital Management LLC 現在擁有 512,338 股該公司的股票，價值 13,377,000 美元，在上個季度又購買了 4,776 股。Vivo Capital LLC 在第三季度將其在 Bright Minds Biosciences 的持股增加了 99.4%。Vivo Capital LLC 現在擁有 501,617 股該公司的股票，價值 30,428,000 美元，在上個季度又收購了 250,045 股。Braidwell LP 在第三季度購買了價值 18,422,000 美元的 Bright Minds Biosciences 新頭寸。Millennium Management LLC 在第一季度將其在 Bright Minds Biosciences 的持股增加了 376.9%。Millennium Management LLC 現在擁有 192,557 股該公司的股票，價值 6,946,000 美元，在此期間又收購了 152,178 股。最後，Balyasny Asset Management L.P. 在第三季度收購了價值 11,339,000 美元的 Bright Minds Biosciences 新頭寸。對沖基金和其他機構投資者持有該公司 40.52% 的股票。</p>
</div><h2>Bright Minds Biosciences Trading Down 3.6%</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 股票下跌 3.6%</h2>
</div><p>NASDAQ DRUG opened at $86.75 on Monday. The business's 50-day moving average price is $73.17 and its 200 day moving average price is $53.97. Bright Minds Biosciences has a twelve month low of $23.17 and a twelve month high of $123.75. The company has a market capitalization of $675.78 million, a PE ratio of -71.11 and a beta of -6.15.</p>
<div class="lb-trans"><p>納斯達克 DRUG 週一開盤價為 86.75 美元。該公司的 50 日移動平均價格為 73.17 美元，200 日移動平均價格為 53.97 美元。Bright Minds Biosciences 的 12 個月低點為 23.17 美元，12 個月高點為 123.75 美元。該公司的市值為 6.7578 億美元，市盈率為-71.11，貝塔值為-6.15。</p>
</div><h2>About Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>關於 Bright Minds Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc. 在納斯達克交易，代碼為 DRUG，是一家臨牀階段的生物技術公司，專注於開發用於心理健康和神經退行性疾病的新型小分子治療藥物。該公司的研究利用專有化學平台創造源自迷幻藥結構的調節血清素和神經保護化合物。Bright Minds 旨在通過口服治療解決重度抑鬱症、創傷後應激障礙和阿爾茨海默病等疾病的未滿足需求。</p>
</div><p>The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.</p>
<div class="lb-trans"><p>該公司的主要候選藥物 BMB-101 是一種口服的 5-HT2A 受體調節化合物，正在臨牀開發中用於情緒和焦慮障礙。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
<li>Huge robotics rollout underway</li>
<li>Do not delete, read immediately</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>New gold price target</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Bright Minds Biosciences</li>
<li>巨大的機器人推廣正在進行中</li>
<li>請勿刪除，立即閲讀</li>
<li>免費：可能改變您生活的加密峯會</li>
<li>新的黃金價格目標</li>
<li>家族信託如何幫助保護您的財富</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRUG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 Bright Minds Biosciences 嗎？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Bright Minds Biosciences 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Bright Minds Biosciences 並不在名單上。</p>
</div><p>While Bright Minds Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bright Minds Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bright Minds Biosciences Inc.（NASDAQ:DRUG）被分析師一致推薦為 “適度買入”